BabU
New member
Pfizer’s New Oral Anti-Viral Drug Lowers Risk of Post-Covid Condition, Study Shows The study further showed that Nirmatrelvir – sold under Paxlovid -- was associated with reduced risk of Post-Covid-Condition in people who were unvaccinated, vaccinated, and boosted, and in people with primary SARS-CoV-2 infection and reinfection